Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood tests could reveal hidden clues in aggressive brain cancer

NCT ID NCT07417774

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: NuvOx LLC Source: ClinicalTrials.gov ↗

First seen Feb 25, 2026 · Last updated May 20, 2026 · Updated 11 times

Summary

This study looks at blood samples from 40 people with glioblastoma, a serious brain cancer, who are also in a larger trial testing an oxygen-boosting drug. The goal is to find markers in the blood that show how the tumor responds to treatment and help doctors tell the difference between true tumor growth and treatment-related changes. This research does not test a new treatment but aims to improve how we monitor the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Center for Neurosciences

    Tucson, Arizona, 85718, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Saint Luke's Cancer Institute

    Kansas City, Missouri, 64111, United States

  • Yale Cancer Center

    New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.